Intravesical gemcitabine for non-muscle invasive bladder cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Intravesical gemcitabine for non-muscle invasive bladder cancer

Published:2012-01-18 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Jones Gabriel¹,Cleves Anne²,Wilt Timothy J³,Mason Malcolm⁴,Kynaston Howard G⁵,Shelley Mike⁶

Affiliation:

1. Research Department, Velindre NHS Trust; Cochrane Prostatic Diseases and Urological Cancers Unit; Cardiff Wales UK CF14 2TL

2. Cardiff University Velindre Hospital; Cancer Research Wales Library; Cardiff Wales UK CF14 2TL

3. VAMC; General Internal Medicine (111-0); One Veterans Drive Minneapolis Minnesota USA 55417

4. Velindre Hospital; Clinical Oncology; Whitchurch Cardiff UK CF4 7XL

5. Cardiff University; Department of Surgery; Heath Park Cardiff Wales UK CF14 4XN

6. Velindre NHS Trust; Cochrane Prostatic Diseases and Urological Cancers Unit, Research Dept; Velindre Road Whitchurch Cardiff Wales UK CF4 7XL

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD009294.pub2/fullpdf

Reference47 articles.

1. Randomised phase III trial on Gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance;Addeo;Journal of Clinical Oncology,2009

2. Bendary L Khalil S Shahin A Nawar N Intravesical gemcitabine versus bacillus Calmette-Guerin (BCG) in treatment of non-muscle invasive bladder cancer: Short term comparative study Conference Proceedings American Urological Association 2011 e664 5

3. Single postoperative instillation of gemcitabine in patients with non-muscle invasive transitional cell carcinoma of the bladder: A randomised, double-blind, placebo controlled phase III multicentre study;Bohle;European Urology,2009

4. Randomised phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder;Gardmark;Urology,2005

5. Gemcitabine versus Bacille Calmette-Guerin after initial Bacille Calmette-Guerin failure in non-muscle invasive bladder cancer;Lorenzo;Cancer,2010

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023;Journal of Urologic Oncology;2023-11-30

2. Efecto de la mitomicina en comparación con la gemcitabina intravesical en el tratamiento del cáncer de vejiga sin invasión muscular: metaanálisis;Actas Urológicas Españolas;2023-03

3. Nicht muskelinvasives Urothelkarzinom der Harnblase;Im Fokus Onkologie;2022-10

4. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022;Journal of the National Comprehensive Cancer Network;2022-08

5. Adjuvante Instillationstherapie des nicht muskelinvasiven Harnblasenkarzinoms – neue Optionen abseits von BCG und Mitomycin;TumorDiagnostik & Therapie;2022-06-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3